Park City, UT

3 days / 6 sessions
Current Issues in Spine

February 2-4, 2017

Implanet-logo-fi-1212-1-1.jpg

October 16, 2018 OrthoSpineNews

October 16, 2018

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News:

IMPLANET (Paris:ALIMP) (OTCQX:IMPZY) (Euronext Growth: ALIMP, FR0010458729, eligible for PEA-PME equity savings plans), a medical technology company specializing in vertebral and knee surgery implants, is today announcing its first surgery Jazz® in Belgium, at the UZ Brussels University Hospital. A further illustration of its direct sales strategy that has proven effective in France and USA.

After the opening of Implanet UK, which along with its Jazz® platform has recently been approved by the UK’s National Health Service, and the opening of Implanet GmbH in Germany, this first surgery in Belgium demonstrates that Implanet is continuing to roll out its products directly in European markets.

Jazz® technology is an excellent solution to be used in addition to screw fixation for preventing pullout in treating degenerative spine disease in adults. In pediatrics Jazz® can also be a replacement for screws in complex spinal deformities. The clinical benefit of Jazz® is undeniable, providing patients with additional safety. I am delighted to have access to the entire Jazz® product range at the University Hospital UZ Brussel, Belgium” says Dr David Van Schaik, orthopedic spine surgeon.

Ludovic Lastennet, CEO of Implanet, said: “This first surgery, which took place only shortly after we announced the opening of Implanet UK and Implanet GmbH in Germany, accelerates the roll-out of our direct sales strategy. We are confident that this model is the right one and will positively impact our earnings going forward.”

Implanet will be attending the following scientific conferences during Q4 2018:

SOFCOT in Paris from November 12 to November 15, 2018, stand F07
BSS (British Scoliosis Society) in Belfast from November 29 to November 30, 2018, stand 9
DWG in Wiesbaden (Germany) from December 6 to December 8, 2018, stand 102

About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ® latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ® has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 46 staff and recorded 2017 sales of €7.8 million. For further information, please visit www.implanet.com.

Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.

IMPLANET is listed on Euronext™ Growth market in Paris. The Company would like to remind that the table for monitoring the BEOCABSA, OCA, BSA and the number of shares outstanding, is available on its website: http://www.implanet-invest.com/suivi-des-actions-80

Contacts

IMPLANET
Ludovic Lastennet
CEO
Tel. : +33 (0)5 57 99 55 55
investors@implanet.com
or
NewCap
Investor Relations
Julie Coulot
Tel. : +33 (0)1 44 71 20 40
implanet@newcap.eu
or
NewCap
Media Relations
Nicolas Merigeau
Tel. : +33 (0)1 44 71 94 98
implanet@newcap.eu
or
AlphaBronze
US-Investor Relations
Pascal Nigen
Tel.: +1 917 385 21 60
implanet@alphabronze.net


KASM-product-image-press-release-12bto3.jpg

October 16, 2018 OrthoSpineNews

OCTOBER 16, 2018 Warsaw, IN – Johnson & Johnson Medical Devices Companies* today announced that DePuy Synthes Sales, Inc. has entered into an exclusive agreement with Ortho Development® Corporation to co-promote in the U.S. its KASM® Knee Articulating Spacer Mold. This is a sterile, disposable cement spacer mold for patients who develop an infection after primary knee replacement. This new offering builds upon DePuy Synthes’** commitment to innovative knee solutions focused on helping patients along the care continuum.

Of the five percent of patients who require total knee revision surgery1, prosthetic joint infections are among the leading cause2, with the majority occurring within the first two years after surgery3. Treating this type of infection requires a two-stage process. The primary knee implant is removed and replaced with a temporary antibiotic knee spacer. When the infection has cleared, the patient then undergoes a second surgery to replace the knee, known as a revision procedure.

Knee spacers are typically either static or articulating. Static spacers require patients to keep the infected knee immobilized for up to six months until the infection has cleared. Articulating spacers allow patients to weight bear with the use of crutches or a walker and possibly maintain motion during their recovery. KASM is designed to help preserve range of motion, joint space and soft tissue tension. Additional KASM features include:

  • Smooth articulating surface for both femur and tibial sides
  • Open mold design that allows surgeons to customize the fill of each component to accommodate for existing bony defects and other patient-specific conditions
  • Three sizes to account for a variety of patient anatomies

“KASM provides us with the unique opportunity to help surgeons whose patients have developed an infection to maintain some mobility and freedom they might not otherwise have had throughout the healing process,” said Juan-José Gonzalez, President, DePuy Synthes U.S. “This exclusive agreement with Ortho Development adds to our existing knee portfolio that spans treatment from early intervention to surgical replacement, with the goal of helping people return to living active and fulfilling lives.”

Ortho Development Corporation designs, develops, manufactures, and markets devices for knee and hip joint reconstruction, spine treatment, and trauma. KASM is one of Ortho Development’s products and received FDA clearance in 2014. This product has also been on the market in Japan for several years.

DePuy Synthes will begin to promote KASM in the latter part of 2018.


About Johnson & Johnson Medical Devices Companies
As the world’s most comprehensive medical devices business, we are building on a century of experience, merging science and technology, to shape the future of health and benefit even more people around the world. With our unparalleled breadth, depth and reach across surgery, orthopaedics and interventional solutions, we’re working to profoundly change the way care is delivered. We are in this for life. For more information, visit www.jnjmedicaldevices.com.

About DePuy Synthes
DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.

*The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, and interventional solutions businesses within the Johnson & Johnson’s Medical Devices segment.
**DePuy Synthes represents the products and services of DePuy Synthes, Inc. and its affiliates.
1 M. Khan, K. Osman, G. Green, F. S. Haddah (2016). The epidemiology of failure in total knee arthroplasty. The Bone & Joint Journal, 98-B (1 Suppl A), 105-12.
2 Current epidemiology of revision total knee arthroplasty in the United States. Delanois R, Mistry J, Gwam C, Mohamed N, Choksi U, Mont M. J Arthroplasty. 2017 Mar; 32:2663-2668.
3 Prosthetic joint infection. Tande A, Patel R. Clinical Microbiology Reviews. 2014; 27(2)302-345.

Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding the agreement with Ortho Development to exclusively promote KASM. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of DePuy Synthes, any of the other Johnson & Johnson Medical Devices Companies and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realized or may take longer to realize than expected; uncertainty of commercial success; challenges to patents; competition, including technological advances, new products and patents attained by competitors; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; changes to applicable laws and regulations, including global health care reforms; changes in behavior and spending patterns of purchasers of health care products and services; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the company’s most recently filed Quarterly Report on Form 10-Q, including under the caption “Cautionary Note Regarding Forward-Looking Statements,” and in the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither the Johnson & Johnson Medical Devices Companies nor Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.


index.6jpg-lightbox-1-12bto-1.jpg

October 16, 2018 OrthoSpineNews

October 16, 2018

PARIS–(BUSINESS WIRE)–Regulatory News:

EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI – Eligible PEA – SME), the pioneer of 2D/3D imaging and data solutions for orthopedics, today announced its (non-audited) consolidated sales for the third quarter ended September 30, 2018.

Marie Meynadier, Chief Executive Officer of EOS imaging, commented, “We continue to build a solid foundation for future growth with strong commercial traction, particularly in the North America and Asia-Pacific regions. This continued momentum was partially offset by temporary delays with several accounts, primarily in EMEA. We view this timing setback as short-term and anticipate a strong catch up in the last quarter of the year, leading to a solid growth for the full year. We are confident and committed to accelerating growth across all three of our major markets as we continue to see our solutions gain traction amongst hospitals and private practices.

  • Nine Month 2018 Sales by Product Line
Sales / non-audited / € millions

As of September, 30

9M 2018 9M 2017 % Change

% Change
excl. forex
impact

Equipment Sales 19.10 19.89 -4% -1%

As % of total sales

75% 80%

Sales of Maintenance

5.76

4.29

+34%

+39%

As % of total sales

23%

17%

Sales of consumables and services

0.65

0.74

-12% -12%

As % of total sales

2%

3%

Total Sales 25.51 24.93 +2% +5%

 

In the first nine months of 2018, EOS imaging generated revenue of €25.5 million, up +2% including forex impact compared to same period prior year, and €26.3 million, up +5%, excluding forex impact.

46 EOS® systems have been sold year-to-date (vs. 51 for the same period last year), with a solid average selling price. Total revenues from equipment sales was €19.1 million, compared to €19.9 million in the same period in 2017.

Due to the increased installed base of EOS® systems, recurring revenues grew +27% to €6.4 million, including €5.8 million in maintenance revenue (+34%) and €0.7 million in consumables and services revenues.

  • Nine Month 2018 Sales by Geography

Revenues / non-audited / € millions
As of September 30

9M 2018 9M 2017 % change
(excl. forex
impact)
EMEA 8.19 11.52 -29%
North America 10.86 9.18 +18% (+27%)
Asia-Pacific 5.75 4.23 +36%
LATAM 0.71
Total revenues 25.51 24.93 +2% (5%)

 

Total revenues for the first nine months of 2018 benefited from the strong commercial traction in North America and Asia-Pacific and were partially offset by continued delays in EMEA regions, where revenue decreased -29% primarily attributed to the three largest EMEA markets of the company (France, United Kingdom, and Germany). In this area, several sales were delayed and are expected to contribute to a strong commercial catch-up in the fourth quarter of 2018.

  • Third Quarter Sales by Product Line
Revenues / non-audited / € millions Q3 2018 Q3 2017 % change
Equipment sales 5.49 6.74 -19%
Sales of maintenance 2.30 1.47 +56%
Sales of consumables and services 0.17 0.25 -32%
Total sales 7.96 8.46 -6%

 

In the third quarter of 2018, the Company generated revenue of €7.96 million, down 6% compared to the third quarter of 2017 (4% excluding forex impact).

The Company sold 12 EOS® systems during the third quarter of 2018, compared to 17 systems in the same period last year. Revenue from equipment sales was €5.5 million, down 19% compared to 2017.

Recurring revenues grew +44% to €2.5 million and represented 31% of total sales compared to 20% of total sales in the same period last year. This includes €2.3 million in maintenance revenue (+56%) and €0.2 million revenue of consumables and services.

About EOS imaging

EOS imaging designs, develops and markets EOS®, a major innovative medical imaging solution dedicated to osteoarticular pathologies and orthopedics combining equipment and services and targeting a $2B per year market opportunity. EOS imaging is currently present in 33 countries, including the United States under FDA agreement, Japan, China and the European Union under CE labelling, through the over 280 installed EOS® platforms representing around one million patient exams every year. Revenues were €37.1M in 2017, e.g. a +32% CAGR over 2012-2017. For more information, please visit www.eos-imaging.com.

EOS imaging has been selected to integrate the EnterNext © PEA – PME 150 index, composed of 150 French, listed companies on the Euronext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

Contacts

EOS imaging
Marie Meynadier
CEO Ph: +33 (0)1 55 25 60 60
investors@eos-imaging.com
or
Investor Relations (US)
Matt Picciano / Emma Poalillo
The Ruth Group
Ph: 646-536-7008 / 7024
EOS-imagingIR@theruthgroup.com
or
Press Relations (US)
Kirsten Thomas
The Ruth Group
Ph: 508-280-6592
kthomas@theruthgroup.com


UCHealth-University-of-Colorado-Hospital-Exterior-sized-2-1200x801.jpg

October 16, 2018 OrthoSpineNews

Aurora, Colo., Oct. 16, 2018 (GLOBE NEWSWIRE) —

The Colorado Department of Public Health and Environment (CDPHE) and American College of Surgeons have verified and designated UCHealth University of Colorado Hospital (UCH) on the Anschutz Medical Campus as a Level I trauma center, making it one of only five hospitals in the state with the highest capabilities for trauma care. The Level I distinction recognizes the hospital’s ability to treat the most severe and complex injuries, giving residents of Aurora, metro Denver, eastern Colorado, and the broader Rocky Mountain region rapid access to the most advanced trauma care.

  • Level I is the highest trauma center designation.
  • University of Colorado Hospital is home to the only American Burn Association Verified Burn Center in Colorado.
  • University of Colorado Hospital has the largest neurological intensive care unit in the state and is one of the few Comprehensive Stroke Centers. 
  • University of Colorado Hospital is home to a full-service orthopedic trauma service and the Limb Restoration Program, dedicated to the treatment of conditions that can put limbs at risk.
  • Nationally recognized surgeons, emergency and trauma physicians from University of Colorado School of Medicine provide expert care for patients.

The hospital received official designation by the Colorado Department of Public Health and Environment on Oct. 12, 2018.

“Earning this Level I designation has taken years of planning and advancements,” said Will Cook, UCHealth University of Colorado Hospital’s president and CEO. “The CU School of Medicine and UCH have recruited some of the nation’s best trauma surgeons, led important research, and improved every aspect of our trauma patient care. This preparation, and the Level I designation, will result in more lives being saved.”

Hospital trauma designations are determined according to established state and national criteria. Key elements required to be a Level I trauma center include around-the-clock coverage by trauma surgeons and prompt availability of the most comprehensive group of specialists in orthopedics, neurosurgery, and anesthesiology, among others. Such facilities also must be leaders in trauma prevention and education, conduct research, and meet volume requirements for treating severely injured patients.

The majority of trauma cases involve blunt injuries that are often the result of incidents such as motor vehicle crashes, pedestrians or bicyclists hit by vehicles, falls, and penetrating trauma injuries such as gunshot wounds and stabbings. UCH also serves as a regional referral destination for patients from dozens of hospitals in Colorado, Wyoming, Kansas and Nebraska.

“Excellent trauma care depends on a large team of specialists, nurses, surgeons, therapists and support staff. Only by working together can we provide patients with the highest level of care possible,” said Dr. Robert McIntyre, the hospital’s trauma medical director and CU School of Medicine professor. “Not only are we providing excellent trauma care today, but the research and education we are leading will help define the future of trauma medicine.”

Patients with the most serious burns often include life-threatening trauma injuries as well, and UCH now provides these patients with the most advanced capabilities for both types of injuries.

“As the first and only Burn Center in our region verified by the American Burn Association, University of Colorado Hospital already cares for patients from a multi-state region, providing a comprehensive team approach to care,” said Dr. Anne Wagner, medical director of the Burn Center and associate professor, CU School of Medicine. “Now these patients can benefit from the highest burn and trauma capabilities at the same location.”

Dave Repsher, a flight nurse and paramedic, was critically injured and burned when the medical transport helicopter he was flying in crashed in Summit County in July 2015. He was rushed to the Burn Center at UCH where he spent more than a year recovering from his injuries.

“I was flown to University of Colorado Hospital, desperately critical, and subsequently received care from an army of caregivers and staff,” Repsher said. “I spent 397 days in the hospital. I have been seen by over 42 specialties and ancillary services, have had 51 major surgeries and countless procedures, all here at the Anschutz Medical Campus. My recovery is due, in no small part, to having all of the dedicated services and specialties I needed including: burn, trauma and transplant all coordinated and centralized in one location.”

EDITORS’ NOTE: Downloadable photos and videos are available here.

About UCHealth

UCHealth is an innovative, nonprofit health system that delivers the highest quality medical care with an excellent patient experience. UCHealth combines Longs Peak HospitalYampa Valley Medical CenterMemorial Hospital CentralMemorial Hospital NorthPoudre Valley HospitalMedical Center of the RockiesUCHealth Medical GroupBroomfield HospitalGrandview HospitalPikes Peak Regional Hospital and University of Colorado Hospital into an organization dedicated to health and providing unmatched patient care in the Rocky Mountain West. With more than 150 clinic locations, UCHealth pushes the boundaries of medicine, providing advanced treatments and clinical trials and improving health through innovation.

Paula Freund
UCHealth
720-848-5809
Paula.Freund@UCHealth.org

hipknee_1_0-12bto2.jpg

October 16, 2018 OrthoSpineNews

10-10-2018

According to the latest study published by AnalystView Market Insights, by the end of 2025, global sports medicine market is expected to reach USD 11.98 billion with the CAGR of 7.5%.

Sports medicine includes the medicines that can be used for treatment and prevention of injuries related to the exercise and sports. Sports medicine is a broad team that involves kinesiologists, physiologists, athlete trainers, physical therapists, physical educators, and many others. The market for sports medicine is primarily driven by the rise in a number of sports injuries across the globe. According to the National Ski Areas Association (NSAA), around 56,714 people were injured while participating in the winter sports that required immediate attention. Winter sports included sports like snowboarding, snowmobiling, and ice skating.

The main objective of introducing sports medicine is to prevent and treat injuries caused to the participants while performing the sports activities. Thereby, a steady introduction of new treatment modalities and products is expected to surge in demand for sports medicine. This, in turn, is expected to drive the market growth. In addition to this, constant developments in regenerative medicine field are expected. This will establish a healthy platform for market growth during the forecast period in this sector. It is also noticed that many multinational companies are planning to increase their investment in the development of 3D printed orthopedic implants which support the market growth to great extent. For instance, in January 2017, Sweden based OssDsign AB received US FDA approval of 3D Printed Cranial Implant Technology to commercialize the product in the U.S. market.

Get access to exclusive PDF brochure of this study @
www.analystviewmarketinsights.com/request_sample/av118/

This introduction is a definite approval as regards the products in this market arena. For instance, a product for cranial bone reconstruction will provide a healthy platform for future market growth. This product segment is divided into Body Monitoring, Body Reconstruction, Body Support, as well as the Sports Accessories. Body reconstruction and support devices collectively captured more than 50% share of the global market. High usage coupled with technological advancement has supported the market growth of these segments. Body monitoring segment is categorized as Cardiac, Hemodynamic, Musculoskeletal, and others. Body Reconstruction is further divided into Surgical equipment, Soft tissue repair, and Bone reconstruction devices. Body support device category is classified into various products like Braces devices, Compression clothing, and Hot & cold therapy. Hot and cold therapy is mainly used to control swelling. It also helps in dilating the blood vessels which supply ample blood to the site providing a stimulus to the process of healing the damaged tissue.

Accessories in this category include bandages, tapes, disinfectants, wraps, along with other instruments such as scissors, cutters, blister packs, etc. Bandages have dominated accessories segment in the year 2016. A sharp increase in incidents of injuries is observed. Thus, infection preventing product range is anticipated to contribute to the growth of this segment. Sports medicine market involving the application segment is categorized as Knees, Shoulders, Back & Spine, Hips, and Others. Knee devices accounted for the largest share of the global market in the year 2016. This segment is anticipated to maintain its leading position with a rising volume of knee surgeries.

Regionally, the market is categorized as North America, Europe, Asia Pacific, and Rest of the World. Around 49.36% share of the global market revenue is captured by North American countries, dominated by the U.S. market. Increase in a number of orthopedic procedures is anticipated owing to the high prevalence of accidents caused during a physical activity. This has supported the sports medicine market growth in this region. For instance, according to the CDC, around 51.4 million orthopedic procedures were performed in the U.S. in the year 2015. The highest prevalence of orthopedic conditions coupled with the high adoption of advanced treatment procedures is fuelling the growth of the market in the U.S.

Asia Pacific region is seen as a promising market growing at 9.1% growth rate over the forecast period. Countries such as India, Japan, and China exhibit their great potential to capture significant revenue share of the total Asia Pacific market. For example, Japan has the presence of a large number of implant manufacturers in this segment. The country has higher healthcare expenditure as compared to the other countries in the region. Moreover, the high adoption rate of the new technology and presence of various accident-prone individual sports in the region are expected to fuel the growth of the sports medicine market.

Companies such as Medtronic, Smith & Nephew, Stryker, Conmed, Wright Medical Technology, and others are present in this market. Company merger & acquisition strategies are being utilized for expanding their geographic presence. It is important to note that Mergers and acquisitions also enable widening of product portfolio as well as the customer base of the companies.

Click here to obtain more highlight on “Sports Medicine Market, By Products, By Application and Geography – Analysis, Share, Trends, Size, & Forecast From 2014 – 2025” study @
www.analystviewmarketinsights.com/report-highlight-sports…

Global Sports Medicine Market: Snapshot

Market, By Products
Body Monitoring (Cardiac, Hemodynamic, Musculoskeletal and Others), Body Reconstruction (Surgical equipment, Soft tissue repair and Bone reconstruction devices), Body Support (Braces devices, Compression clothing and Hot & cold therapy), and Sports Accessories (Bandages, Tapes, Disinfectants, Wraps and others)

Market, By Application
Knees, Shoulders, Back & Spine, Hips and others
Market, by Region
North America (U.S. and Canada), Europe (France and Germany), Asia Pacific (India and China), Middle East and Africa, Latin America and Rest of the World

Key players profiled in this report with special attention on competitive landscape includes, (can be further customized to include additional 10 profiles of companies):
– Medtronic
– Smith & Nephew
– Stryker Corporation
– Conmed
– Wright Medical Technology

USP of our key vendor analysis:
– Well-designed strategic framework design for these key players will help to understand the market movement including regional expansion, mergers & acquisitions, and new product developments
– Thorough SWOT i.e. Strength, Weakness, Opportunities and Threat for individual company profiling is analyzed in order to present a detailed market opportunity assessment.

Key benefits of the report:
• The report presents a macro and micro-level outlook regarding the industry. Thus, it becomes easy for our clients to perceive the business landscape and take a glimpse of their own standing in it.
• A thorough analysis of relevant statistical data to estimate the market paradigms
• Exceptional understanding of region and country-specific markets. The report will answer some of the toughest questions regarding the market shares, sizes, forecasts segmentations, and growth specific to the countries.
• Well-designed strategic framework analyzes the market movements including regional expansion, mergers & acquisitions, and new product developments

Research Methodology:
– Preliminary Data Mining: Secondary Research, Paid Databases, Primary Research
– Data Synthesis & Analysis: Top-Down Approach, Bottom-Up Approach, Supply Side and Demand Side
– Market Formulation: Market Dynamics, Total Addressable Market and Machine Learning Technique
– Data Verification: Quality Assurance and Reach a Conclusion

To inquire more about our research process and report store, please connect @
www.analystviewmarketinsights.com/get-in-touch/

About Us
AnalystView Market Insights is a market research and consulting firm that adopts a proactive approach to provide the diverse need for accurate and precise market research, custom research, and consulting solutions across geographies and industry verticals. We strive to develop meaningful and evidence-based research data that helps our clients, empowering organizations and brands of all sizes with strategic analysis, accurate data, and consumer trends for various industries such as Healthcare, Bulk Chemicals, Semiconductors, Electronics, and Foods and Beverages.

Contact Us
Mr. Jose (Press & Marketing Manager)
Corporate Sales, USA
AnalystView Market Insights
Email: sales@analystviewmarketinsights.com
Tel: +91-757-498-5725 (Asia-Pacific Business Centre)
Web: www.analystviewmarketinsights.com

This release was published on openPR.


hospital-for-special-surgery-123-1-1.jpg

October 16, 2018 OrthoSpineNews

NEW YORKOct. 16, 2018 /PRNewswire/ — An unprecedented $10 million grant from the Stavros Niarchos Foundation (SNF) has been given to Hospital for Special Surgery (HSS) to name the Complex Joint Reconstruction Center (CJRC). This new commitment will support the endowment of the CJRC for the operation and expansion of its clinical, research and educational programs.

According to the American Joint Replacement Registry, there are over 7 million Americans living with replaced hip and knee joints and, should they fail, treatment is complex and requires specialized management.

“This generous gift will improve the lives of countless patients who suffer from debilitating complications or need revision surgery due to failed implants,” said Thomas P. Sculco, MD, surgeon-in-chief emeritus and director of the CJRC at HSS. “We are deeply honored by the visionary leadership of the SNF in supporting our endeavor to lessen implant failure, restore function, and relieve pain for patients who need specialized joint reconstructions.”

As the first of its kind, the Stavros Niarchos Foundation Complex Joint Reconstruction Center provides the best in diagnosis and treatment for patients with the most challenging conditions in joint reconstructions, regardless of their financial circumstances, and conducts cutting-edge basic and clinical research on the causes and prevention of implant failure.

“Having partnered with HSS for over a decade, the SNF has witnessed first-hand the deep commitment of the people of HSS to excellence and progress in orthopedic care,” said Andreas Dracopoulos, Co-President of the SNF. “We are especially proud to support Dr. Sculco’s vision to improve the lives of patients with the most complex cases of joint reconstruction, and to seek solutions to issues that impact the field at large.”

“HSS is uniquely positioned to develop new techniques and improvements in implant design that will significantly impact global care for these complex problems.” said Dr. Sculco. “People are living longer and leading more active lives thus making the need for progress in our knowledge and treatment of these failed implants more critical than ever.”

Dr. Sculco is internationally recognized as a leader in hip and knee replacement surgery, having pioneered minimally invasive surgical techniques. Now, he is leading efforts to improve the success and longevity of implants to benefit millions of patients worldwide.

Over the past year, the CJRC has expanded its surgical team to 16 experienced orthopedic surgeons and successfully launched a patient registry with over 800 surgical cases already recorded. This registry is the first in the world solely dedicated to capturing vital clinical and outcomes data from patients undergoing joint reconstruction and complex primary joint replacement surgery. This data creates a platform for clinical trials, translational research and innovations in treatment that will lead to improved standards of care. In 2017, the CJRC performed 534 surgeries on patients with complex joint reconstructions.

The Stavros Niarchos Foundation is one of the world’s leading private international philanthropic organizations, making grants in the areas of health and sports, arts and culture, education, and social welfare. The SNF supports projects that aim to achieve a broad, lasting and positive impact on society.

Spanning over a decade, HSS and SNF’s longstanding relationship has spurred programs such as the Stavros Niarchos Foundation-Thomas P. Sculco, MD International Orthopaedic Fellowship Program, HSS Stavros Niarchos Foundation Orthopaedic Seminar and Academic Visitor Program to educate Greek orthopedic surgeons on ways to improve treatment and outcomes in joint replacement.

Since 2006, HSS has hosted Greek surgeons for the annual HSS Stavros Niarchos Foundation Orthopaedic Seminar Program, which teaches the latest techniques and innovations in complex and primary total hip and knee replacement with the ultimate goal of improving healthcare in Greece.

This year, the seminar will take place on November 27-28, 2018 with two days of didactic sessions, case consultations, roundtable discussions, hands-on workshops and operating room observation at operations at HSS. The following three days will include attendance at the 30th Annual HSS Holiday Knee & Hip Course, a CME-accredited professional education course.

The program immerses visiting Greek surgeons, typically those early in their careers, in the high-volume joint replacement environment at HSS.

SNF also previously granted HSS $1 million to fund the Thomas P. Sculco, Chair in Orthopedic Surgery, which played an instrumental role in the creation of the CJRC.

About HSS | Hospital for Special Surgery
HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the ninth consecutive year) and No. 3 in rheumatology by U.S.News & World Report (2018-2019). Founded in 1863, the Hospital has one of the lowest infection rates in the country and was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. The global standard total knee replacement was developed at HSS in 1969. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New JerseyConnecticut and in the Long Island and Westchester County regions of New York State. In 2017 HSS provided care to 135,000 patients and performed more than 32,000 surgical procedures. People from all 50 U.S. states and 80 countries travelled to receive care at HSS. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Global Innovation Institute was formed in 2016 to realize the potential of new drugs, therapeutics and devices. The culture of innovation is accelerating at HSS as 130 new idea submissions were made to the Global Innovation Institute in 2017 (almost 3x the submissions in 2015). The HSS Education Institute is the world’s leading provider of education on the topic on musculoskeletal health, with its online learning platform offering more than 600 courses to more than 21,000 medical professional members worldwide. Through HSS Global Ventures, the institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally.

About the Stavros Niarchos Foundation
The Stavros Niarchos Foundation [(SNF) (www.SNF.org)] is one of the world’s leading private, international philanthropic organizations, making grants in the areas of arts and culture, education, health and sports, and social welfare. Since 1996, the Foundation has committed more than $2.6 billion, through more than 4,000 grants to nonprofit organizations in 124 nations around the world.

The SNF funds organizations and projects, worldwide, that aim to achieve a broad, lasting and positive impact, for society at large, and exhibit strong leadership and sound management. The Foundation also supports projects that facilitate the formation of public-private partnerships as an effective means for serving public welfare.

SOURCE Hospital for Special Surgery

Related Links

http://www.hss.edu


machine-12bto-1.png

October 16, 2018 OrthoSpineNews

October 16, 2018

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between surgeons and patients to improve minimally invasive surgery, today announced demonstrations of its Senhance™ Surgical System at the American College of Surgeons (ACS) Clinical Congress 2018 at the Boston Convention & Visitors Center in Boston, MA, October 21 – 25.

Surgeons, Hospital Administrators and related staff are invited to experience Senhance Surgery during the Company’s daily demonstrations located at the TransEnterix booth #577, from Monday, October 22 – Wednesday, October 24 from 10:30 a.m. – 11:30 a.m. ET. Participants will witness how digital laparoscopy is redefining minimally invasive surgery through meaningful technology, designed to compete in today’s value-based healthcare landscape. To schedule a demonstration in advance, visit transenterix.com/events.

“Digital laparoscopy with the Senhance System provides a digitized interface between the surgeon and patient, giving surgeons improved control, comfort, clinical intelligence and confidence when performing a wide variety of procedures with the goal of delivering superior value to more patients,” said TransEnterix Chief Commercial Officer, Eric Smith. “We look forward to attending ACS and demonstrating how digital laparoscopy with the Senhance is ushering in a new era of minimally invasive surgery.”

The Senhance Surgical System received U.S. FDA clearance in October 2017 and represents the first robotic surgery platform to enter the U.S. market since 2000. It is the only digital laparoscopic platform available that offers reusable instruments to help keep costs down, as well as haptic feedback, which allows surgeons to experience and sense pressure/tension with alerts if pressure threshold is reached – an added layer of security. The System combines much-needed technological advances with economic advantages and represents a fundamental change in the approach to minimally invasive surgery.

About TransEnterix

TransEnterix is a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today’s value-based healthcare environment. The Company is focused on the commercialization of the Senhance Surgical System, which digitizes laparoscopic minimally invasive surgery. The system allows for robotic precision, haptic feedback, surgeon camera control via eye sensing and improved ergonomics while offering responsible economics. The Senhance Surgical System is available for sale in the US, the EU and select other countries. For more information, visit www.transenterix.com.

Forward Looking Statements

This press release includes statements relating to the Senhance Surgical System and our current regulatory and commercialization plans for this product. These statements and other statements regarding our future plans and goals constitute “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether the Senhance System will usher in a new era of minimally invasive surgery. For a discussion of the risks and uncertainties associated with TransEnterix’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K filed on March 8, 2018, and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Contacts

TransEnterix, Inc.
Investor Contact:
Mark Klausner, 443-213-0501
transenterix@westwicke.com
or
Media Contact:
Joanna Rice, 951-751-1858
joanna@greymattermarketing.com


AMPLITUDE-1-123-1-1-1.jpg

October 15, 2018 OrthoSpineNews

October 15, 2018

VALENCE, France–(BUSINESS WIRE)–Regulatory News:

Amplitude Surgical (ISIN: FR0012789667, Ticker: AMPLI, PEA-PME eligible) (Paris:AMPLI), a leading French player on the global surgical technology market for lower-limb orthopedics, announces the appointment of Mrs. Muriel Benedetto Marmilloud to the newly-created position of Chief Operating Officer (COO). She will report directly to Olivier Jallabert, Chairman and CEO of Amplitude Surgical.

Olivier Jallabert, Chairman and CEO of Amplitude Surgical, says: “All of Amplitude Surgical’s staff members and I are delighted to welcome Muriel Benedetto Marmilloud to the newly-created position of Chief Operating Officer. Muriel is a senior executive who is recognized for her focus on innovation and her knowledge of global markets – in particular the US market. Her experience and strategic vision will be very valuable to our Group’s future growth, its global deployment and the expansion of its portfolio of innovative products”.

Graduated from the ECAM engineering school in Lyon, Muriel Benedetto Marmilloud has over twenty years of experience in the orthopedic medical device sector. She has notably been the global director of a product line generating over a billion-dollar at Zimmer Biomet, the global leader of this sector.

Muriel Benedetto Marmilloud will work alongside Chairman and CEO Olivier Jallabert, more focused on the Group’s strategic developments, and in particular international development. She will be in charge of steering the R&D, Supply chain and Quality assurance & Regulatory affairs departments, in order to ensure total control over the entire logistics value chain. Working in close collaboration with the current teams, she will also be responsible for continuing the structuring of operations in order to accompany the Company’s international development and comply with future regulatory changes.

About Amplitude Surgical
Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player on the global surgical technology market for lower-limb orthopedics. Amplitude Surgical develops and markets high-end products for orthopedic surgery covering the main disorders affecting the hip, knee and extremities, and notably foot and ankle surgery. Amplitude Surgical develops, in close collaboration with surgeons, numerous high value-added innovations in order to best meet the needs of patients, surgeons and healthcare facilities. A leading player in France, Amplitude Surgical is developing abroad through its subsidiaries and a network of exclusive distributors and agents distributing its products in more than 30 countries. Amplitude Surgical operates on the lower-limb market through the intermediary of its Novastep subsidiaries in France and the United States. At June 30, 2018, Amplitude Surgical had a workforce of nearly 400 employees and recorded sales of over 100 million euros.

Contacts

Amplitude Surgical
Philippe Garcia, +33 (0)4 75 41 87 41
CFO
finances@amplitude-surgical.com
or
NewCap
Investor Relations
Marc Willaume, +33 (0)1 44 71 00 13
amplitude@newcap.eu
or
NewCap
Media Relations
Nicolas Merigeau, +33 (0)1 44 71 98 55
amplitude@newcap.eu


1491601885513-Y-1-1-1-1-1.png

October 15, 2018 OrthoSpineNews

WARSAW, Ind.Oct. 15, 2018 /PRNewswire/ — Zimmer Biomet Holdings, Inc., a global leader in musculoskeletal healthcare, is working with Apple by using Apple Watch and iPhone to change the patient journey for two of the most common surgeries Americans undergo each year – knee and hip replacement. This collaboration has yielded Zimmer Biomet mymobility™, an app that uses Apple Watch to facilitate a new level of connection between patients and their surgical care teams, which can immediately impact the journey patients experience when they undergo these procedures.

In addition to the app, Zimmer Biomet is commencing the mymobility Clinical Study, designed to study the app’s impact on patient outcomes and overall costs for joint replacement patients. During this research study, patients will use Zimmer Biomet mymobility with Apple Watch as they progress through their hip or knee replacement journey. Researchers will combine patient-reported feedback with continuous health and activity data from Apple Watch to provide new insights into the power of the Zimmer Biomet mymobility app to impact the standard of care for these common surgeries. The study is launching today and has the possibility to enroll as many as 10,000 patient participants in the United States.

“We are incredibly excited to work with Apple to transform the knee and hip replacement experience for patients and surgeons,” said Bryan Hanson, President and CEO, Zimmer Biomet. “At Zimmer Biomet, we are committed to improving care decisions through digital health and we are thrilled to launch one of the largest evidence-gathering clinical studies in orthopaedic history.”

“We believe one of the best ways to empower consumers is by giving them the ability to use their health and activity information to improve their own care,” said Jeff Williams, Chief Operating Officer, Apple. “We are proud to enable knee and hip replacement patients to use their own data and share it with their doctors seamlessly, so that they can participate in their care and recovery in a way not previously possible through traditional in-person visits. This solution will connect consumers with their doctors continuously, before and after surgery.”

More than one million knee and hip replacements occur annually in the U.S. This number is expected to grow to 3.5 million by 2035, yet standardization of care and recovery for the procedures is still lacking and costs to the U.S. healthcare system continue to rise. Zimmer Biomet mymobility and Apple Watch will act as a virtual and continuous care team on a patient’s wrist. Patients will be provided with support and guidance as they prepare for and recover from these surgeries, while surgeons will be delivered continuous data to optimize care. The new Zimmer Biomet mymobility app has several features that use both Apple Watch and iPhone through the joint replacement journey, including the ability for surgeons to send education and therapy reminders directly to the patient’s Apple Watch. The app also allows surgeons to monitor patient activity levels throughout the days and weeks while they are preparing for and recovering from surgery.

Facilities participating in the mymobility Clinical Study include:

  • Academic centers: University of Utah Health; Rush University Medical Center; University of Pennsylvania Health System; Emory University Orthopaedics & Spine Hospital/Emory Healthcare
  • Hospitals: Hoag Orthopedic Institute in Southern California; Newton-Wellesley Hospital, member of Partners HealthCare founded by Massachusetts General Hospital and Brigham and Women’s Hospital; Centura Health, Porter Hospital – Colorado Joint Replacement (CJR)
  • Group practices/ambulatory surgery centers: ROC Orthopedics, affiliated with Legacy Meridian Park Medical Center; OrthoBethesda; OrthoArizona; Midwest Center for Joint Replacement; Hartzband Center for Hip & Knee Replacement; New Mexico Orthopaedic Associates; The DeClaire LaMacchia Orthopaedic Institute, affiliated with Michigan Institute for Advanced Surgery; Joint Implant Surgeons; Orthopedic and Fracture Clinic; Panorama Orthopedic and Spine Center

To learn more about the mymobility Clinical Study, visit  zbmymobility.com/clinical-study.

Apple, Apple Watch and iPhone are registered trademarks of Apple, Inc.

About the Company 
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com.

Contacts:

Media
Jon Siegal 
781-684-6557 
jon.siegal@mslgroup.com

SOURCE Zimmer Biomet Holdings, Inc.

Related Links

http://www.zimmerbiomet.com


image-12bto-1.jpg

October 15, 2018 OrthoSpineNews

BELGRADE, MT, Oct. 15, 2018 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today the appointment of Michael Mainelli to serve as Interim Chief Executive Officer, replacing Carl O’Connell effective October 12, 2018.

Mr. Mainelli joined the Board of Directors in February 2018 and will remain a member of the Board of Directors while serving as Interim Chief Executive Officer. The Company intends to commence a process to recruit a permanent Chief Executive Officer that will include both internal and external candidates.

Mr. Mainelli commented, “I am excited to continue working with our Board and with our management team in my new role. Xtant has great products, strong business partners, and dedicated, talented employees.  We will be working hard to drive superior execution.”

Mr. Jeff Peters, Chairman of the Board, stated that “Mike is a proven leader with over 25 years of successful business leadership in the medical technology industry. He has led businesses at both public and private medical technology companies resulting in growth, operational improvement, and enhanced shareholder value. His unique experience in the global orthopaedic and spinal markets will be particularly valuable, and we are pleased to have him in this interim role.”

Mr. Mainelli succeeds Carl O’Connell, who served as Xtant’s Chief Executive Officer since October 2016. Mr. Peters added, “On behalf of the Board, I want to thank Carl O’Connell for his dedication and contributions, notably guiding the company through the recent restructuring process.  We wish Carl all the best.”

About Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Important Cautions Regarding Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as ‘‘expects,’’ ‘‘anticipates,’’ ‘‘intends,’’ ‘‘plans,’’ ‘‘believes,’’ ‘‘estimates,’’ “continue,” “future,” ‘‘will,’’ “can,” similar expressions or the negative thereof, and the use of future dates. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company’s future operating results and financial performance; the ability to increase revenue; the ability to remain competitive; the ability to innovate and develop new products; the effect of management changes and the ability to engage and retain qualified personnel; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals; government regulations; product liability claims and other litigation to which we may be subject; product recalls and defects; timing and results of clinical studies; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; the ability to service Company debt and comply with debt covenants; the ability to raise additional financing and other factors. Additional risk factors are contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the Securities and Exchange Commission (SEC) on April 2, 2018 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2018 filed with the SEC on August 8, 2018. Investors are encouraged to read the Company’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.

COMPANY CONTACT
Kathie Lenzen, Chief Financial Officer
406.388.0480
klenzen@xtantmedical.com